Middle East Cell Gene Therapy Cdmo Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The MEA cell and gene therapy CDMO market encompasses contract service providers that support the development, manufacturing, and commercialization of advanced therapies including autologous cell therapies, allogeneic cell therapies, and viral vector-based gene therapies. The market has emerged as a significant player in the global biopharmaceutical outsourcing landscape, with the region's $7.58 billion valuation in 2025 representing a rapidly growing share of the global ATMP manufacturing market. This expansion is underpinned by substantial investments in state-of-the-art manufacturing facilities, including aseptic production capabilities and modular biomanufacturing infrastructure designed to accommodate the high-mix, low-volume production requirements characteristic of cell and gene therapies.

• •Market valued at $7.58 billion in 2025 with 25.06% annual growth trajectory
• •Focus on advanced therapy medicinal products (ATMPs) including cell and gene therapies
• •Investment in modular and reconfigurable manufacturing facilities for high-mix production

The market's exceptional growth is primarily fueled by geographic shifts in biopharmaceutical manufacturing as companies seek to diversify supply chains and reduce dependency on traditional manufacturing regions. Digital transformation initiatives, including the adoption of digital twin technology in biomanufacturing operations, are enhancing production efficiency and quality control capabilities across regional CDMO facilities. Additionally, the increasing complexity of cell and gene therapy products, which require specialized aseptic processing and personalized manufacturing approaches, has created sustained demand for contract manufacturing partnerships with providers possessing advanced technical capabilities.

• •Geographic diversification of biopharmaceutical supply chains driving investment in emerging markets
• •Digital twin and Industry 4.0 technologies improving manufacturing efficiency and quality assurance
• •Growing pipeline of ATMPs requiring specialized contract manufacturing capacity

The Middle East, particularly the Gulf Cooperation Council countries, dominates the regional CDMO activity, with the United Arab Emirates establishing itself as a hub through initiatives such as the Abu Dhabi Stem Cells Center, which manufactures CAR-T cell therapies. South Africa and other sub-Saharan markets represent emerging segments with growing clinical trial activity and developing manufacturing infrastructure. The market spans both autologous and allogeneic cell therapy manufacturing, as well as viral vector production for gene therapy applications, with varying levels of capacity development across different therapeutic categories and geographic sub-regions.

• •UAE leads regional capacity with facilities like Abu Dhabi Stem Cells Center producing CAR-T therapies
• •South Africa and sub-Saharan markets showing emerging CDMO development
• •Coverage spans autologous cell therapy, allogeneic cell therapy, and viral vector manufacturing

What are the recent trends and outlook?

The market is positioned for sustained double-digit growth through the remainder of the decade as regional governments continue prioritizing biotechnology and advanced therapy manufacturing as part of economic diversification strategies. Continued adoption of modular and continuous manufacturing technologies will enable CDMO providers to efficiently serve the personalized medicine market while maintaining compliance with increasingly stringent global regulatory standards. Strategic partnerships between regional CDMOs and global pharmaceutical developers are expected to accelerate technology transfer and capacity building, further strengthening the MEA region's position in the global cell and gene therapy manufacturing ecosystem.

• •Government-backed biotechnology initiatives driving long-term infrastructure development
• •Modular manufacturing technologies enabling flexible capacity for personalized cell therapies
• •Strategic alliances between regional and global CDMOs accelerating technology transfer